Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.
本文提供了化合物及其药物组合物,用于调节SHP2,并在治疗疾病方面的应用。
Preparation of 1,5-Dihydropyrazolo[3′,4′:5,6]pyrano[3,4-<i>b</i>]pyridines via a Microwave-Assisted, Palladium-Catalyzed Regioselective C–H Heteroarylation of Electron-Rich Pyrazoles
作者:Aaron T. Garrison、Elizabeth S. Childress、Dexter C. Davis、Craig W. Lindsley
DOI:10.1021/acs.joc.9b00144
日期:2019.5.3
Here we report the first synthesis of a family of novel heterocyclic compounds based on a 5-dihydropyrazolo[3',4':5,6]pyrano[3,4-b]pyridine core. In the course of our drug discovery programs, we had need to access the previously unknown 5-dihydropyrazolo[3',4':5,6]pyrano[3,4-b]pyridine core. Initial attempts required long reaction times, which led to degradation and side products. Reaction optimization identified a Pd-catalyzed, microwave-assisted C-H heteroarylation protocol for the rapid, general, and high yielding synthesis of this tricyclic core (as well as related analogs) suitable to drive optimization efforts.
PROTEIN TYROSINE PHOSPHATASE INHIBITORS
申请人:Array Biopharma, Inc.
公开号:EP3947367A1
公开(公告)日:2022-02-09
[EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE
申请人:ARRAY BIOPHARMA INC
公开号:WO2020201991A1
公开(公告)日:2020-10-08
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
[EN] PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLOPYRAZINE UTILISÉS COMME INHIBITEURS DE LA SHP2
申请人:[en]GENZYME CORPORATION
公开号:WO2023114954A1
公开(公告)日:2023-06-22
Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.